You are here: Industry Insights > LNS8801

News List

Additional Cohorts to Evaluate LNS8801 in Combination with KEYTRUDA(R) in Patients with Advanced Cancer americanpharmaceuticalreview
June 17, 2021
Linnaeus Therapeutics Inc. announced the expansion of its ongoing clinical collaboration with Merck to include multiple additional phase 2 cohorts.
Linnaeus Granted Orphan Drug Designation for LNS8801 for Metastatic Uveal Melanoma americanpharmaceuticalreview
March 18, 2021
Linnaeus Therapeutics announced the U.S. Food and Drug Administration (FDA) has granted orphan drug designation for LNS8801 for the treatment of patients with metastatic uveal melanoma (MUM).
First Patient Dosed in Trial of LNS8801, KEYTRUDA Combination in Advanced Cancer americanpharmaceuticalreview
October 19, 2020
Linnaeus Therapeutics has dosed the first patient in its phase 1/2 adaptive-design clinical trial of its lead-product-candidate, LNS8801, in combination with KEYTRUDA® (pembrolizumab) in patients who had previous clinical benefit from immune checkpoint...
Linnaeus Announces Clinical Trial Collaboration Agreement with Merck americanpharmaceuticalreview
July 03, 2020
Linnaeus Therapeutics has entered into a clinical collaboration agreement with Merck to evaluate the combination of its lead investigational product candidate LNS8801, and Merck's anti-PD-1 therapy ...
Linnaeus Announces FDA Clearance of IND Application for LNS8801 americanpharmaceuticalreview
September 26, 2019
Linnaeus Therapeutics announced the U.S. Food and Drug Administration (FDA) has cleared the company's investigational new drug application (IND) for LNS8801 ...